遠大醫藥(00512.HK):TLX250-CDx於澳洲完成拓展適應症膀胱癌首例患者給藥
格隆匯7月7日丨遠大醫藥(00512.HK)發佈公吿,集團在放射性核素偶聯藥物(RDC)領域的合作伙伴Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”)用於診斷透明細胞腎細胞癌(“ccRCC”) 的全球創新型放射性核素偶聯藥物TLX250-CDx(89Zr-DFO-girentuximab) (“TLX250- CDx”)近日在拓展的適應症尿路上皮癌或膀胱癌中,於澳洲完成了 I 期臨牀研究的首例患者給藥。根據集團與Telix簽訂的授權協議,該產品拓展的適應症包括在集團被授予的產品權益範圍內。
放射性核素藥物是集團在抗腫瘤領域中重點佈局的戰略方向之一。集團將攜手重要的聯營公司澳洲 Sirtex Medical Pty Ltd和參股公司Telix,針對尚未滿足的臨牀需求,加大對放射性藥物領域全球創新產品的投入及開發,豐富和完善產品管線及產業佈局,致力於打造國際領先的放射性藥物診療平台。
集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為驅動,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“全球化運營佈局,雙循環經營發展”策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的診療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.